Possible genomic imprinting of three human obesity-related genetic loci
The FDA withdrew several compounded peptides from pharmacy dispensing in early 2024, including BPC-157 and TB-500, citing lack of approved drug application status
A licensed provider will review your health profile and create a personalized plan
The relationship of vitamin B12 to carbohydrate metabolism and diabetes mellitus
Liver enzymes at 12 weeks for any peptide used at high dose or in combination
Researched applications In the published preclinical and clinical literature the effects of AOD-9604 are documented in the following areas: Obesity , Phase 2b failure (2007), but a complementary mechanism in combination protocols Lipolysis in animal models , robustly demonstrated (Heffernan 2001, Ng 2009) Inhibition of lipogenesis , demonstrated in hepatocytes and adipocytes Osteoarthritis and cartilage regeneration , emerging Phase 1/2 data (mLuna Pharmaceuticals 2018+) Tendinopathy , preclinical models Age-related sarcopenia (cachexia) , exploratory plans Lipodystrophy , preclinical data in animal models Hyperlipidemia , secondary endpoints in Phase 2 trials Science & studies 4.1 Key publications Heffernan M., Summers R.J., Thorburn A., et al